Skip to main content
. 2021 Nov 26;24(12):103517. doi: 10.1016/j.isci.2021.103517

Figure 6.

Figure 6

DON attenuates ISO-induced cardiac hypertrophy in vivo

(A) Representative immunoblots of protein O-GlcNAcylation and GAPDH in ISO (15 mg/kg body weight/day, 7 days)- or control vehicle (saline) treated-C57B/6J mouse hearts subjected to either 6-Diazo-5-oxo-L-norleucine (DON, 0.05 mg/kg body weight/day) or saline for 7 days. Quantitative analysis of protein O-GlcNAcylation in ISO- or control vehicle-treated C57B/6J mouse hearts subjected to either DON (0.05 mg/kg body weight/day) or saline for 7 days (n = 9).

(B) The representative echocardiographic images of ISO- or control vehicle-treated C57B/6J mouse hearts subjected to either DON (0.05 mg/kg body weight/day) or saline for 7 days. Long two-way arrows and short two-way arrows indicate left ventricular end-diastolic diameter (LVDd) and left ventricular end-systolic diameter (LVDs), respectively.

(C–F) Wall thickness, LVDd, LVDs, and LV ejection fraction (LVEF) measured by echocardiography at day 7 in each group (n = 12).

(G) Heart weight to tibial length (TL) ratio and LV weight to TL ratio in each group (n = 12).

(H) Masson-trichrome-stained heart section in each group. Scale bar, 50 μm. Cardiomyocyte hypertrophy as assessed by cross-sectional area in each group (n = 6).

(I) Expression of atrial natriuretic factor (ANF) and 18S mRNA in the indicated mouse hearts (n = 6). ∗p < 0.05, ∗∗p < 0.01: post hoc Tukey's comparison test.